Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology Class A Ordinary Shares Fundamental Analysis
Anbio Biotechnology Class A Ordinary Shares (NNNN) shows moderate financial fundamentals with a PE ratio of 387.10, profit margin of 37.47%, and ROE of 11.40%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 70.6/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze NNNN's fundamental strength across five key dimensions:
Efficiency Score
WeakNNNN struggles to generate sufficient returns from assets.
Valuation Score
WeakNNNN trades at a premium to fair value.
Growth Score
ModerateNNNN shows steady but slowing expansion.
Financial Health Score
ExcellentNNNN maintains a strong and stable balance sheet.
Profitability Score
ModerateNNNN maintains healthy but balanced margins.
Key Financial Metrics
Is NNNN Expensive or Cheap?
P/E Ratio
NNNN trades at 387.10 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, NNNN's PEG of 90.23 indicates potential overvaluation.
Price to Book
The market values Anbio Biotechnology Class A Ordinary Shares at 33.79 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 389.33 times EBITDA. This signals the market has high growth expectations.
How Well Does NNNN Make Money?
Net Profit Margin
For every $100 in sales, Anbio Biotechnology Class A Ordinary Shares keeps $37.47 as profit after all expenses.
Operating Margin
Core operations generate 25.78 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.40 in profit for every $100 of shareholder equity.
ROA
Anbio Biotechnology Class A Ordinary Shares generates $8.69 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Anbio Biotechnology Class A Ordinary Shares produces operating cash flow of $1.60M, showing steady but balanced cash generation.
Free Cash Flow
Anbio Biotechnology Class A Ordinary Shares generates strong free cash flow of $1.60M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.04 in free cash annually.
FCF Yield
NNNN converts 0.15% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
387.10
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
90.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
33.79
vs 25 benchmark
P/S Ratio
Price to sales ratio
145.03
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
211.10
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How NNNN Stacks Against Its Sector Peers
| Metric | NNNN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 387.10 | 29.43 | Worse (Expensive) |
| ROE | 11.40% | 800.00% | Weak |
| Net Margin | 37.47% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 211.10 | 4.64 | Strong Liquidity |
| ROA | 8.69% | -17936.00% (disorted) | Weak |
NNNN outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Anbio Biotechnology Class A Ordinary Shares's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation